{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:22:57Z","timestamp":1790252577597,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanofi S.p.A"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02648-1","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:15:16Z","timestamp":1740759316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database"],"prefix":"10.1186","volume":"24","author":[{"given":"Antonio","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Zilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Baccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Baronti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Falcetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelio","family":"Morviducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Musacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Muselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ozzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Verda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vezenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ponzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2648_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83. https:\/\/doi.org\/10.1186\/s12933-018-0728-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2648_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archinte.163.1.33","volume":"163","author":"AD Mooradian","year":"2003","unstructured":"Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med. 2003;163:33. https:\/\/doi.org\/10.1001\/archinte.163.1.33.","journal-title":"Arch Intern Med"},{"key":"2648_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313\u201330.","journal-title":"Eur Heart J"},{"key":"2648_CR4","doi-asserted-by":"publisher","first-page":"e2317","DOI":"10.1210\/clinem\/dgae092","volume":"109","author":"MK Kim","year":"2024","unstructured":"Kim MK, Lee KN, Han K, Lee S-H. Diabetes duration, cholesterol levels, and risk of cardiovascular diseases in individuals with type 2 diabetes. J Clin Endocrinol Metab. 2024;109:e2317\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"2648_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154. https:\/\/doi.org\/10.1186\/s12933-021-01344-0.","journal-title":"Cardiovasc Diabetol"},{"key":"2648_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2337\/dci18-0007","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917\u201328.","journal-title":"Diabetes Care"},{"key":"2648_CR7","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Cardiovascular disease and risk management: standards of care in diabetes\u20142023. Diabetes Care. 2023;46:S158\u201390.","journal-title":"Diabetes Care"},{"key":"2648_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"2648_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diabres.2017.12.004","volume":"137","author":"K Khunti","year":"2018","unstructured":"Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137\u201348.","journal-title":"Diabetes Res Clin Pract"},{"key":"2648_CR10","doi-asserted-by":"publisher","first-page":"e0259157","DOI":"10.1371\/journal.pone.0259157","volume":"16","author":"L Feng","year":"2021","unstructured":"Feng L, Lam A, Carmody D, Lim CW, Tan G, Goh S-Y, et al. Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry. PLoS ONE. 2021;16:e0259157. https:\/\/doi.org\/10.1371\/journal.pone.0259157.","journal-title":"PLoS ONE"},{"key":"2648_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20:685\u201395.","journal-title":"Nat Rev Cardiol"},{"key":"2648_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wi d e cross-section a l obser v at i o n al study of lipid-modifying therapy use in Se c ondary and Pr i mary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"2648_CR13","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Europe. 2023;29:100624.","journal-title":"Lancet Reg Health Europe"},{"key":"2648_CR14","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","volume":"31","author":"KK Ray","year":"2024","unstructured":"Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferri\u00e8res J, et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31:1792\u2013803.","journal-title":"Eur J Prev Cardiol"},{"key":"2648_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1177\/2047487319831476","volume":"26","author":"RD Santos","year":"2019","unstructured":"Santos RD. Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. Eur J Prev Cardiolog. 2019;26:820\u20133.","journal-title":"Eur J Prev Cardiolog."},{"key":"2648_CR16","doi-asserted-by":"publisher","first-page":"111743","DOI":"10.1016\/j.diabres.2024.111743","volume":"213","author":"G Russo","year":"2024","unstructured":"Russo G, De Cosmo S, Di Bartolo P, Lucisano G, Manicardi V, Nicolucci A, et al. The quality of care in type 1 and type 2 diabetes\u2014A 2023 update of the AMD Annals initiative. Diabetes Res Clin Pract. 2024;213:111743.","journal-title":"Diabetes Res Clin Pract"},{"key":"2648_CR17","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s40618-024-02327-0","volume":"47","author":"A Da Porto","year":"2024","unstructured":"Da Porto A, Candido R, Rocca A, Manicardi V, Nicolucci A, Miranda C, et al. Quality of care and clinical inertia in the management of cardiovascular risk factors in patients with type 1 and type 2 diabetes: data from AMD annals. J Endocrinol Invest. 2024;47:2595\u2013602. https:\/\/doi.org\/10.1007\/s40618-024-02327-0.","journal-title":"J Endocrinol Invest"},{"key":"2648_CR18","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140.","journal-title":"Eur Heart J"},{"key":"2648_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/ph17030289","volume":"17","author":"L De Oliveira","year":"2024","unstructured":"De Oliveira L, De Assis A, Giraldez V, Scudeler T, Soares P. Dyslipidemia: a narrative review on pharmacotherapy. Pharmaceuticals. 2024;17:289.","journal-title":"Pharmaceuticals"},{"key":"2648_CR20","doi-asserted-by":"publisher","first-page":"22603","DOI":"10.1038\/s41598-021-02077-6","volume":"11","author":"L Inglin","year":"2021","unstructured":"Inglin L, Lavikainen P, Jalkanen K, Laatikainen T. LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. Sci Rep. 2021;11:22603.","journal-title":"Sci Rep"},{"key":"2648_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","volume":"19","author":"ML Morieri","year":"2020","unstructured":"Morieri ML, Avogaro A, Fadini GP, The DARWIN-T2D Network of the Italian Diabetes Society. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. Cardiovasc Diabetol. 2020;19:190.","journal-title":"Cardiovasc Diabetol"},{"key":"2648_CR22","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","volume":"28","author":"AM Cebri\u00e1n-Cuenca","year":"2022","unstructured":"Cebri\u00e1n-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltr\u00e1n D, Consuegra-S\u00e1nchez L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: data from a large Mediterranean population. Eur J Prev Cardiol. 2022;28:e32\u20134.","journal-title":"Eur J Prev Cardiol"},{"key":"2648_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-021-01251-4","volume":"20","author":"B Pintaudi","year":"2021","unstructured":"Pintaudi B, Scatena A, Piscitelli G, Frison V, Corrao S, Manicardi V, et al. Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study. Cardiovasc Diabetol. 2021;20:59. https:\/\/doi.org\/10.1186\/s12933-021-01251-4.","journal-title":"Cardiovasc Diabetol"},{"key":"2648_CR24","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1111\/dom.15763","volume":"26","author":"W Wang","year":"2024","unstructured":"Wang W, Qiao J, Zhang L, Zhang J, Luo J, Chen C, et al. Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: a population-based cross-sectional screening study. Diabetes Obes Metab. 2024;26:4251\u201360. https:\/\/doi.org\/10.1111\/dom.15763.","journal-title":"Diabetes Obes Metab"},{"key":"2648_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/2047487320908698","volume":"28","author":"K Kotseva","year":"2021","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryd\u00e9n L, Hoes A, Grobbee D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021;28:370\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"2648_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.numecd.2023.09.023","volume":"34","author":"M Berteotti","year":"2024","unstructured":"Berteotti M, Profili F, Nreu B, Casolo G, Zuppiroli A, Mannucci E, et al. LDL-cholesterol target levels achievement in high-risk patients: an (un)expected gender bias. Nutr Metab Cardiovasc Dis. 2024;34:145\u201352.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2648_CR27","doi-asserted-by":"publisher","first-page":"107141","DOI":"10.1016\/j.vph.2023.107141","volume":"148","author":"U Laufs","year":"2023","unstructured":"Laufs U, Catapano AL, De Caterina R, Schiele F, Sionis A, Zaman A, et al. The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vasc Pharmacol. 2023;148:107141.","journal-title":"Vasc Pharmacol"},{"key":"2648_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","volume":"21","author":"M Banach","year":"2022","unstructured":"Banach M, Surma S, Reiner Z, Katsiki N, Penson PE, Fras Z, et al. Personalized management of dyslipidemias in patients with diabetes\u2014it is time for a new approach (2022). Cardiovasc Diabetol. 2022;21:263. https:\/\/doi.org\/10.1186\/s12933-022-01684-5.","journal-title":"Cardiovasc Diabetol"},{"key":"2648_CR29","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"2648_CR30","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/jcm12124095","volume":"12","author":"D Masi","year":"2023","unstructured":"Masi D, Zilich R, Candido R, Giancaterini A, Guaita G, Muselli M, et al. Uncovering predictors of lipid goal attainment in type 2 diabetes outpatients using logic learning machine: insights from the AMD annals and AMD Artificial Intelligence Study Group. JCM. 2023;12:4095.","journal-title":"JCM"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02648-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02648-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02648-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:15:18Z","timestamp":1740759318000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02648-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02648-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and all participating diabetes centers obtained the authorization of local Ethics Committees. All data were anonymized, and no direct patient involvement was required, ensuring compliance with ethical standards and data protection regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"According to Italian Law 211\/2003, no consent is required for epidemiological analysis regarding anonymous data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}